FRANKLIN
LAKES, N.J., Jan. 15,
2025 /PRNewswire/ -- BD (Becton, Dickinson and
Company) (NYSE: BDX), a leading global medical technology company,
today announced additional investments in its U.S. manufacturing
network to add capacity for critical medical devices, including
syringes, needles and IV catheters, to meet the ongoing needs of
the nation's health care system.
As part of the company's 2024 investment of more than
$10 million to expand manufacturing
capacity, new needle and syringe production lines have been
installed at the BD plants in Connecticut and Nebraska. One line is already fully
operational with additional lines expected to start up in the
coming months.
These new lines will boost BD's capacity of domestically
manufactured safety-engineered injection devices by more than 40
percent and conventional syringes by more than 50 percent, adding
hundreds of millions of units annually to support critical U.S.
health care delivery such as hospital procedures, vaccinations,
medication preparation and drug delivery to patients. In addition,
BD has hired more than 215 full-time employees at its facilities in
Nebraska and Connecticut to support the increased
production.
BD also has plans for more than $30
million in investments in 2025 to expand manufacturing
capacity for IV lines at its plant in Utah to support continued growth in catheter
solutions. This follows the company's 2024 investment of more than
$2 million for IV line improvements
that resulted in increased IV catheter output by more than 40
million units annually.
"Domestic manufacturing is crucial for ensuring a resilient
supply of essential health care devices," said Eric Borin, president of Medication Delivery
Solutions at BD. "By expanding our production capacity, we are not
only meeting the critical needs of patients and providers, but we
also are reinforcing our commitment to the nation's health care
infrastructure."
The investments underscore the company's ongoing commitment and
deep legacy in supporting U.S. health care supply chain resilience
through the domestic manufacturing of critical medical devices.
Increasing supply capacity builds on the company's more than 120
years of manufacturing excellence across the United States. In Nebraska, Connecticut and Utah alone, the company has collectively 200
years of experience in manufacturing critical medical devices.
BD in Columbus, Neb. opened in 1949, and today spans 1
million square feet and employs more than 2,000 people across three
locations. BD in Canaan, Conn.
opened in 1961, and today spans 385,000 square feet and employs
more than 540 people. These sites are the only remaining
large-scale syringe manufacturing sites in the U.S. The BD site in
Sandy, Utah opened in 1956 and
employs approximately 1,200 associates with 650,000 square feet of
operations. It is the largest producer of IV catheter lines in the
world.
BD operates more than 30 manufacturing and distribution
facilities in the United States,
which represent an important part of the backbone of the U.S.
medical product supply chain. These facilities employ more than
10,000 people and are spread across 17 states and Puerto Rico.
About BD
BD is one of the largest global medical
technology companies in the world and is advancing the world of
health by improving medical discovery, diagnostics and the delivery
of care. The company supports the heroes on the frontlines of
health care by developing innovative technology, services and
solutions that help advance both clinical therapy for patients and
clinical process for health care providers. BD and its more than
70,000 employees have a passion and commitment to help enhance the
safety and efficiency of clinicians' care delivery process, enable
laboratory scientists to accurately detect disease and advance
researchers' capabilities to develop the next generation of
diagnostics and therapeutics. BD has a presence in virtually every
country and partners with organizations around the world to address
some of the most challenging global health issues. By working in
close collaboration with customers, BD can help enhance outcomes,
lower costs, increase efficiencies, improve safety and expand
access to health care. For more information on BD, please visit
bd.com or connect with us on LinkedIn at
www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or
Instagram @becton_dickinson.
Contacts:
|
|
|
|
|
|
Media:
|
|
Investors:
|
Alyssa
Kretlow
|
|
Adam
Reiffe
|
BD Public
Relations
|
|
Sr. Director, Investor
Relations
|
551.238.4391
|
|
201.847.6927
|
alyssa.kretlow@bd.com
|
|
adam.reiffe@bd.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bd-boosts-us-manufacturing-of-critical-medical-devices-302351311.html
SOURCE BD (Becton, Dickinson and Company)